Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.

Front Pharmacol · 2023 · PMC10658783 · PMID 38026920

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp = 0.00001actually significant

3.2 Response to ETI therapy initiation Effects of ETI therapy assessed with averaged CFAbd-day2day © responses revealed a highly significant decrease in the median total score ( p = 0.00001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.